Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic c...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Rabia Yılmaz
2022-11-01
|
| Saila: | Journal of Contemporary Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://dergipark.org.tr/tr/download/article-file/2653132 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|